DnB Asset Management AS grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.8% during the fourth quarter, HoldingsChannel reports. The firm owned 85,848 shares of the medical research company’s stock after purchasing an additional 2,300 shares during the period. DnB Asset Management AS’s holdings in Thermo Fisher Scientific were worth $16,301,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Amalgamated Bank boosted its stake in shares of Thermo Fisher Scientific by 57.0% during the second quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after purchasing an additional 16,308 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 2.1% during the second quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after purchasing an additional 977 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Thermo Fisher Scientific by 0.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after purchasing an additional 5,213 shares in the last quarter. San Francisco Sentry Investment Group CA acquired a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $1,451,000. Finally, Huntington National Bank lifted its stake in shares of Thermo Fisher Scientific by 2.4% in the third quarter. Huntington National Bank now owns 195,348 shares of the medical research company’s stock worth $36,959,000 after acquiring an additional 4,655 shares during the period. 86.22% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on TMO shares. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. Leerink Swann lifted their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research note on Monday, October 9th. Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective on the stock. Finally, Evercore ISI started coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and a consensus price target of $212.21.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a return on equity of 9.09% and a net margin of 10.44%. The firm’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.03 earnings per share. equities analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s payout ratio is currently 10.19%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the sale, the chief executive officer now directly owns 252,577 shares in the company, valued at $47,582,981.03. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.49% of the company’s stock.
WARNING: This piece of content was reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2018/01/11/thermo-fisher-scientific-inc-tmo-shares-bought-by-dnb-asset-management-as.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.